PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) and Savara (NASDAQ:SVRA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for PMV Pharmaceuticals and Savara, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PMV Pharmaceuticals | 1 | 0 | 1 | 1 | 2.67 |
| Savara | 1 | 0 | 6 | 1 | 2.88 |
PMV Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 358.72%. Savara has a consensus target price of $10.14, indicating a potential upside of 100.45%. Given PMV Pharmaceuticals’ higher possible upside, equities research analysts clearly believe PMV Pharmaceuticals is more favorable than Savara.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PMV Pharmaceuticals | N/A | N/A | -$77.74 million | ($1.49) | -0.73 |
| Savara | N/A | N/A | -$118.84 million | ($0.56) | -9.04 |
Savara is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares PMV Pharmaceuticals and Savara’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PMV Pharmaceuticals | N/A | -68.98% | -62.70% |
| Savara | N/A | -87.19% | -66.42% |
Volatility & Risk
PMV Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.
Summary
PMV Pharmaceuticals beats Savara on 8 of the 11 factors compared between the two stocks.
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
